Redeye sees a soft Q2 report from Stille, marked by headwinds in the surgical instruments business, ...
Redeye states that the Q2 report came in broadly in line with our expectations, with a high YoY net ...
Redeye comments on Evolutions Q2-results, which were in line with our expectations, albeit with slig...
Redeye provides its first take on Camurus’ Q2 report 2025, published this morning.
Net sales and EBIT were slightly below market consensus (LSEG) in Q2.
Redeye believes Enea’s share price has further to run following the positive market reaction to its ...
Redeye updates its estimates and valuation for Serstech following the Q2 2025 report.
Selective recruitment in H2'25 Q2 missed on sales and adj.
Servicebolaget Coor rapporterade ett starkt kvartal som överträffade vår prognos.
Redeye comments on the conversion of warrants and Cantargia's deal yesterday.
Finnair’s Q2 revenue fell a bit short of estimates as ticket prices developed slightly softer than e...
Redeye comments on the news that the FDA has granted ACD440 orphan drug designation (ODD) for the tr...
Redeye returns with a more in-depth take on the Q2 report.
Redeye comments on CMS’s preliminary CPT-I codes payment rates.
On 15 July 2025, Føroya Banki raised its 2025 net profit guidance range to DKK 235-265m (previously ...
